Skip to main content
Top
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Research article

Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses

Authors: Paul Geerts, Guadalupe Martinez, Andreas Schreiner

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

Discontinuation of antipsychotic treatment for schizophrenia can interrupt improvement and exacerbate the illness. Reasons for discontinuing treatment are multifactorial and include adherence, efficacy and tolerability issues. Poor adherence may be addressed through non-pharmacological approaches as well as through pharmacological ones, ie ensured delivery of medication, such as that achieved with long-acting injectable (LAI) antipsychotics. However, attitudes of healthcare professionals (HCPs) towards LAI antipsychotics may influence their prescribing decisions and may influence medication choices offered to patients. We therefore conducted a survey to investigate factors driving LAI use as well as physician and nurse attitudes to LAI antipsychotics and to different injection sites.

Methods

An independent market research agency conducted the survey of HCPs across Europe. Participants were recruited by telephone and completed the survey online. Using conjoint analyses (a multivariate statistical technique analysing preferences on the basis of ranking a limited number of attributes which are presented repetitively), attitudes to oral versus LAI medication and gluteal versus deltoid injection routes were assessed.

Results

A total of 891 HCPs across Europe were surveyed. Of these, 40% would choose LAI antipsychotics for first episode patients whereas 90% would select LAI antipsychotics for chronic patients with two to five psychotic episodes. Dominant elements in antipsychotic choice were low sedation but no tardive dyskinesia, no or mild pain at injection and low risk of embarrassment or impact upon therapeutic alliance. Eighty-six per cent of respondents considered that having the choice of a deltoid as well as gluteal administration site was beneficial over not having that choice. Two thirds of respondents said they agreed that medication administration via the deltoid muscle may reduce social embarrassment associated with LAI antipsychotics and most respondents (61%) believed that administration of LAI antipsychotics into the deltoid muscle as opposed to the gluteal muscle may be more respectful to the patient.

Conclusions

In this survey of physicians and nurses, attitudes towards LAI antipsychotics compared with oral medication were generally positive. Respondents considered that the availability of a deltoid administration route would offer increased choice in LAI antipsychotic administration and may be perceived as more respectful and less socially embarrassing.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed
2.
go back to reference Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003, 29: 15-31. 10.1093/oxfordjournals.schbul.a006986.CrossRefPubMed Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003, 29: 15-31. 10.1093/oxfordjournals.schbul.a006986.CrossRefPubMed
3.
go back to reference Fleischhacker WW, Keet IPM, Kahn RS: The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005, 78: 147-156. 10.1016/j.schres.2005.06.004.CrossRefPubMed Fleischhacker WW, Keet IPM, Kahn RS: The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005, 78: 147-156. 10.1016/j.schres.2005.06.004.CrossRefPubMed
4.
go back to reference Perkins DO, Hongbin G, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, Comparison of Atypicals in First Episode study group: Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008, 69: 106-113. 10.4088/JCP.v69n0114.CrossRefPubMed Perkins DO, Hongbin G, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, Comparison of Atypicals in First Episode study group: Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008, 69: 106-113. 10.4088/JCP.v69n0114.CrossRefPubMed
5.
go back to reference Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Liberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999, 56: 241-247. 10.1001/archpsyc.56.3.241.CrossRefPubMed Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Liberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999, 56: 241-247. 10.1001/archpsyc.56.3.241.CrossRefPubMed
6.
go back to reference Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM: Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010, 176: 109-113. 10.1016/j.psychres.2009.05.004.CrossRefPubMed Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM: Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010, 176: 109-113. 10.1016/j.psychres.2009.05.004.CrossRefPubMed
7.
go back to reference Wiersma D, Nienhuis FJ, Slooff CJ, Giel R: Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull. 1998, 24: 75-85. 10.1093/oxfordjournals.schbul.a033315.CrossRefPubMed Wiersma D, Nienhuis FJ, Slooff CJ, Giel R: Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull. 1998, 24: 75-85. 10.1093/oxfordjournals.schbul.a033315.CrossRefPubMed
8.
go back to reference Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004, 55: 886-891. 10.1176/appi.ps.55.8.886.CrossRefPubMed Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004, 55: 886-891. 10.1176/appi.ps.55.8.886.CrossRefPubMed
9.
go back to reference Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006, 67: 453-460. 10.4088/JCP.v67n0317.CrossRefPubMed Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006, 67: 453-460. 10.4088/JCP.v67n0317.CrossRefPubMed
10.
go back to reference Masand PS, Roca M, Turner MS, Kane JM: Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatr. 2009, 11: 147-154. 10.4088/PCC.08r00612.CrossRef Masand PS, Roca M, Turner MS, Kane JM: Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatr. 2009, 11: 147-154. 10.4088/PCC.08r00612.CrossRef
11.
go back to reference Velligan DI, Weiden PJ, Sajatovic M, Carpenter D, Ross R, Docherty JP: Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009, 70 (Suppl 4): 1-46.PubMed Velligan DI, Weiden PJ, Sajatovic M, Carpenter D, Ross R, Docherty JP: Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness: The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009, 70 (Suppl 4): 1-46.PubMed
12.
go back to reference Herings RM, Erkens JA: Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003, 12: 423-424. 10.1002/pds.837.CrossRefPubMed Herings RM, Erkens JA: Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003, 12: 423-424. 10.1002/pds.837.CrossRefPubMed
13.
go back to reference Alia-Klein N, O’Rourke TM, Goldstein RZ, Malaspina D: Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav. 2007, 33: 86-96. 10.1002/ab.20170.CrossRefPubMed Alia-Klein N, O’Rourke TM, Goldstein RZ, Malaspina D: Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav. 2007, 33: 86-96. 10.1002/ab.20170.CrossRefPubMed
14.
go back to reference Knapp M, King D, Pugner K, Lapuerta P: Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004, 184: 509-516. 10.1192/bjp.184.6.509.CrossRefPubMed Knapp M, King D, Pugner K, Lapuerta P: Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004, 184: 509-516. 10.1192/bjp.184.6.509.CrossRefPubMed
15.
go back to reference Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004, 161: 692-699. 10.1176/appi.ajp.161.4.692.CrossRefPubMed Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004, 161: 692-699. 10.1176/appi.ajp.161.4.692.CrossRefPubMed
16.
go back to reference Sun SX, Liu GG, Christensen DB, Fu AZ: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007, 23: 2305-2312. 10.1185/030079907X226050.CrossRefPubMed Sun SX, Liu GG, Christensen DB, Fu AZ: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007, 23: 2305-2312. 10.1185/030079907X226050.CrossRefPubMed
17.
go back to reference Gerlach J: Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr Scand Suppl. 1994, 382: 28-32.CrossRefPubMed Gerlach J: Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatr Scand Suppl. 1994, 382: 28-32.CrossRefPubMed
18.
go back to reference NICE Clinical Guideline 82 – Schizophrenia. 2009 NICE Clinical Guideline 82 – Schizophrenia. 2009
19.
go back to reference McEvoy JP: Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006, 67 (Suppl 5): 15-18.PubMed McEvoy JP: Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006, 67 (Suppl 5): 15-18.PubMed
20.
go back to reference Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A: Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010, 26: 501-509. 10.1185/03007990903488670.CrossRefPubMed Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A: Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010, 26: 501-509. 10.1185/03007990903488670.CrossRefPubMed
21.
go back to reference Peuskens J, Mertens C, Kusters J, Paquet V, Van der Veken J, Jacobs A: Long-acting risperidone in the treatment of schizophrenia: data from a 24-month Belgian electronic schizophrenia adherence registry (eSTAR): an observational study. Acta Psychiatr Belg. 2010, 110: 34-46. Peuskens J, Mertens C, Kusters J, Paquet V, Van der Veken J, Jacobs A: Long-acting risperidone in the treatment of schizophrenia: data from a 24-month Belgian electronic schizophrenia adherence registry (eSTAR): an observational study. Acta Psychiatr Belg. 2010, 110: 34-46.
22.
go back to reference Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J: Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008, 30: 2378-2386. 10.1016/j.clinthera.2008.12.020.CrossRefPubMed Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J: Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008, 30: 2378-2386. 10.1016/j.clinthera.2008.12.020.CrossRefPubMed
23.
go back to reference Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D: Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010, 167: 181-189. 10.1176/appi.ajp.2009.07081221.CrossRefPubMed Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D: Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010, 167: 181-189. 10.1176/appi.ajp.2009.07081221.CrossRefPubMed
24.
go back to reference Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E: Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010, 35: 2367-2377. 10.1038/npp.2010.111.CrossRefPubMedPubMedCentral Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E: Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010, 35: 2367-2377. 10.1038/npp.2010.111.CrossRefPubMedPubMedCentral
25.
26.
go back to reference Risperdal™ Consta™ Summary of Product Characteristics: Janssen Pharmaceuticals. 2010, Bucks, UK: High Wycombe Risperdal™ Consta™ Summary of Product Characteristics: Janssen Pharmaceuticals. 2010, Bucks, UK: High Wycombe
27.
go back to reference Thyssen A, Rusch S, Herben V, Quiroz J, Mannaert E: Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol. 2010, 50: 1011-1021. 10.1177/0091270009355156.CrossRefPubMed Thyssen A, Rusch S, Herben V, Quiroz J, Mannaert E: Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol. 2010, 50: 1011-1021. 10.1177/0091270009355156.CrossRefPubMed
28.
go back to reference Zypadhera™ Summary of Product Characteristics. 2008, Houten, The Netherlands: Eli Lilly Nederland BV Zypadhera™ Summary of Product Characteristics. 2008, Houten, The Netherlands: Eli Lilly Nederland BV
29.
go back to reference Invega® Sustenna® Product Information. 2010, Titusville, NJ, USA: Janssen Pharmaceuticals Invega® Sustenna® Product Information. 2010, Titusville, NJ, USA: Janssen Pharmaceuticals
30.
go back to reference Xeplion™ Summary of Product Characteristics: Janssen Pharmaceuticals. 2011, Bucks, UK: High Wycombe Xeplion™ Summary of Product Characteristics: Janssen Pharmaceuticals. 2011, Bucks, UK: High Wycombe
31.
go back to reference Heres S, Hamann J, Kissling W, Leucht S: Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006, 67: 1948-1953. 10.4088/JCP.v67n1216.CrossRefPubMed Heres S, Hamann J, Kissling W, Leucht S: Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry. 2006, 67: 1948-1953. 10.4088/JCP.v67n1216.CrossRefPubMed
32.
go back to reference Jaeger M, Rossler W: Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010, 175: 58-62. 10.1016/j.psychres.2008.11.003.CrossRefPubMed Jaeger M, Rossler W: Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010, 175: 58-62. 10.1016/j.psychres.2008.11.003.CrossRefPubMed
33.
go back to reference Heres S, Schmitz FS, Leucht S, Pajonk FG: The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007, 22: 275-282. 10.1097/YIC.0b013e3280c28424.CrossRefPubMed Heres S, Schmitz FS, Leucht S, Pajonk FG: The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007, 22: 275-282. 10.1097/YIC.0b013e3280c28424.CrossRefPubMed
34.
go back to reference Patel MX, De Zoysa N, Bernadt M, David A: Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol. 2009, 23: 789-796. 10.1177/0269881108092124.CrossRefPubMed Patel MX, De Zoysa N, Bernadt M, David A: Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol. 2009, 23: 789-796. 10.1177/0269881108092124.CrossRefPubMed
35.
go back to reference Caroli F, Raymondet P, Izard I, Plas J, Gall B, Delgado A: Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011, 5: 165-171.CrossRefPubMedPubMedCentral Caroli F, Raymondet P, Izard I, Plas J, Gall B, Delgado A: Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011, 5: 165-171.CrossRefPubMedPubMedCentral
36.
go back to reference Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS: Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010, 24: 1473-1482. 10.1177/0269881109104882.CrossRefPubMed Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS: Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010, 24: 1473-1482. 10.1177/0269881109104882.CrossRefPubMed
37.
go back to reference Waddell L, Taylor M: Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009, 195: s43-s50. 10.1192/bjp.195.52.s43.CrossRef Waddell L, Taylor M: Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009, 195: s43-s50. 10.1192/bjp.195.52.s43.CrossRef
38.
go back to reference The Gale Encyclopedia of Nursing and Allied Health (Five Volume Set). Thomson Gale 2001 edition The Gale Encyclopedia of Nursing and Allied Health (Five Volume Set). Thomson Gale 2001 edition
39.
go back to reference Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M: Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33: 1022-1031. 10.1016/j.pnpbp.2009.05.014.CrossRefPubMed Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M: Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33: 1022-1031. 10.1016/j.pnpbp.2009.05.014.CrossRefPubMed
41.
go back to reference Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006, 67: 1542-1550. 10.4088/JCP.v67n1008.CrossRefPubMed Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006, 67: 1542-1550. 10.4088/JCP.v67n1008.CrossRefPubMed
42.
go back to reference Alonso J, Croudace T, Brown J, Gasquet I, Knapp MR, Suárez D, Novick D: Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health. 2009, 12: 536-543. 10.1111/j.1524-4733.2008.00495.x.CrossRefPubMed Alonso J, Croudace T, Brown J, Gasquet I, Knapp MR, Suárez D, Novick D: Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health. 2009, 12: 536-543. 10.1111/j.1524-4733.2008.00495.x.CrossRefPubMed
43.
go back to reference Patel MX, Nikolaou V, David AS: Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003, 33: 83-89.CrossRefPubMed Patel MX, Nikolaou V, David AS: Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003, 33: 83-89.CrossRefPubMed
44.
go back to reference Patel MX, DE Zoysa N, Baker D, David AS: Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005, 12: 237-244. 10.1111/j.1365-2850.2004.00826.x.CrossRefPubMed Patel MX, DE Zoysa N, Baker D, David AS: Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005, 12: 237-244. 10.1111/j.1365-2850.2004.00826.x.CrossRefPubMed
45.
go back to reference Lloyd K, Latif MA, Simpson S, Shrestha KL: Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum Psychopharmacol. 2010, 25: 243-252. 10.1002/hup.1108.CrossRefPubMed Lloyd K, Latif MA, Simpson S, Shrestha KL: Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome. Hum Psychopharmacol. 2010, 25: 243-252. 10.1002/hup.1108.CrossRefPubMed
46.
go back to reference Macfadden W, Bossie CA, Turkoz I, Haskins JT: Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol. 2010, 25: 75-82. 10.1097/YIC.0b013e3283347cbf.CrossRefPubMed Macfadden W, Bossie CA, Turkoz I, Haskins JT: Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol. 2010, 25: 75-82. 10.1097/YIC.0b013e3283347cbf.CrossRefPubMed
47.
go back to reference Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG: Risperidone Long-Acting Trial Investigators (R-LAI): Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2009, 24: 574-583. 10.1002/hup.1067.CrossRefPubMed Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG: Risperidone Long-Acting Trial Investigators (R-LAI): Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2009, 24: 574-583. 10.1002/hup.1067.CrossRefPubMed
48.
go back to reference Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J: A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010, 30: 235-244. 10.1097/JCP.0b013e3181dd3103.CrossRefPubMed Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J: A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010, 30: 235-244. 10.1097/JCP.0b013e3181dd3103.CrossRefPubMed
49.
go back to reference Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D: A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010, 35: 2072-2082. 10.1038/npp.2010.79.CrossRefPubMedPubMedCentral Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D: A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010, 35: 2072-2082. 10.1038/npp.2010.79.CrossRefPubMedPubMedCentral
50.
go back to reference Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D: A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011, 25: 686-697.CrossRef Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D: A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011, 25: 686-697.CrossRef
51.
go back to reference Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M: Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010, 13: 635-647. 10.1017/S1461145709990988.CrossRefPubMed Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M: Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010, 13: 635-647. 10.1017/S1461145709990988.CrossRefPubMed
Metadata
Title
Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses
Authors
Paul Geerts
Guadalupe Martinez
Andreas Schreiner
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-58

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue